Lexeo Therapeutics (LXEO) EBITDA (2022 - 2023)
Historic EBITDA for Lexeo Therapeutics (LXEO) over the last 2 years, with Q4 2023 value amounting to -$15.0 million.
- Lexeo Therapeutics' EBITDA rose 146.74% to -$15.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$68.5 million, marking a year-over-year change of. This contributed to the annual value of -$98.4 million for FY2024, which is 4826.04% down from last year.
- According to the latest figures from Q4 2023, Lexeo Therapeutics' EBITDA is -$15.0 million, which was up 146.74% from -$20.3 million recorded in Q3 2023.
- Lexeo Therapeutics' 5-year EBITDA high stood at -$14.0 million for Q2 2023, and its period low was -$20.3 million during Q3 2023.